Branched DNA-based Alu quantitative assay for cell-free plasma DNA levels in patients with sepsis or systemic inflammatory response syndrome  by Hou, Yan-Qiang et al.
Journal of Critical Care 31 (2016) 90–95
Contents lists available at ScienceDirect
Journal of Critical Care
j ourna l homepage: www. jcc journa l .o rgBranched DNA-based Alu quantitative assay for cell-free plasma DNA
levels in patients with sepsis or systemic inﬂammatory
response syndromeYan-Qiang Hou, PhD a,⁎,1, Dong-Yu Liang, MD a,1, Xiao-Li Lou, MD a, Mei Zhang, PhD b,
Zhen-huan Zhang, PhD b, Lu-rong Zhang, PhD b
a Department of Central Laboratory, Songjiang Hospital Afﬁliated First People's Hospital, Shanghai Jiao Tong University, Shanghai 201600, China
b Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610
a b s t r a c ta r t i c l e i n f o⁎ Corresponding author. Tel.: +86 2167720946; fax: +
E-mail address: houyanqiang@aliyun.com (Y.-Q. Hou)
1 Yan-Qiang Hou and Dong-Yu Liang contributed equal
http://dx.doi.org/10.1016/j.jcrc.2015.10.013
0883-9441/© 2015 The Authors. Published by Elsevier IncKeywords:
Cell-free DNA
bDNA-based Alu assay
Sepsis
Biomarkers
DiagnosisCell-free circulating DNA (cf-DNA) can be detected by various of laboratory techniques.Wedescribed a branched
DNA–based Alu assay for measuring cf-DNA in septic patients. Compared to healthy controls and systemic in-
ﬂammatory response syndrome (SIRS) patients, serum cf-DNA levels were signiﬁcantly higher in septic patients
(1426.54 ± 863.79 vs 692.02 ± 703.06 and 69.66 ± 24.66 ng/mL). The areas under the receiver operating char-
acteristic curve of cf-DNA for normal vs sepsis and SIRS vs sepsis were 0.955 (0.884-1.025), and 0.856 (0.749-
0.929), respectively. There was a positive correlation between cf-DNA and interleukin 6 or procalcitonin or
Acute Physiology and Chronic Health Evaluation II. The cf-DNA concentration was higher in intensive care unit
nonsurviving patients compared to surviving patients (2183.33 ± 615.26 vs 972.46 ± 648.36 ng/mL; P b .05).
Branched DNA–based Alu assays are feasible and useful to quantify serum cf-DNA levels. Increased cf-DNA levels
in septic patients might complement C-reactive protein and procalcitonin in a multiple marker format. Cell-free
circulating DNA might be a new marker in discrimination of sepsis and SIRS.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic inﬂammatory response syndrome (SIRS) is an inﬂam-
matory condition that affects the entire body. It is frequently a re-
sponse to a wide spectrum of conditions, including burns, trauma,
infection, and surgery [1]. The current criteria for SIRS diagnosis are
based on any combination of fever from hypothermia, tachycardia,
tachypnea, leukocytosis, or leukopenia. Sepsis is syndrome of infec-
tion complicated by organ failure [1]. Despite improvements in diag-
nostic and therapeutic techniques, sepsis remains a major cause of
death in the intensive care unit (ICU), and delayed diagnoses and in-
tervention are usually associated with high mortality [2,3]. Most pa-
rameters for SIRS diagnosis are either nonspeciﬁc or insensitive for a
sepsis diagnosis. One study reported that early diagnosis of sepsis
and appropriate use of antibodies could effectively reduce patient
mortality [3]. Furthermore, avoiding unnecessary antimicrobial
therapy may also reduce the cost of care.
To date, a variety of indicators have been studied for the diagnosis
of sepsis, including acute phase proteins (C-reactive protein [CRP]),86 2167720300.
.
ly to this work.
. This is an open access article undercytokines (interleukin 6 [IL-6], interleukin 8, tumor necrosis factor
α), and procalcitonin (PCT). However, the accuracy and speciﬁcity
of each of these indicators are still in question for the diagnosis of
sepsis [4-7]. In addition, none can strictly differentiate sepsis from
noninfectious SIRS [8]. Thus, it is imperative to ﬁnd a novel marker
that can diagnose sepsis with high speciﬁcity and is easy to mea-
sure, with low cost and rapid application.
Circulating nucleic acids in human peripheral blood were identi-
ﬁed in 1984 by Mandel and Metais [9,10]. Increased cell-free circu-
lating DNA (cf-DNA) has been reported in various diseases,
including trauma, cancer, stroke, and myocardial infarction [11-15].
Although the exact mechanism is poorly understood, available evi-
dence shows that cell lysis, necrosis, apoptosis, and active release
might be related to circulating DNA production [16-19]. Apoptosis
plays an important role in the pathophysiology of sepsis, and cf-
DNA has been found in the plasma of septic patients [20]. Therefore,
it is important to investigate whether cf-DNA increases in SIRS and
septic patients and to determine its role in the diagnosis and differ-
ential diagnosis of sepsis.
In the present study, novel branched DNA (bDNA)–based Alu assays
were used to examine the serum cf-DNA in healthy subjects, SIRS patients,
and septic patients in an effort to evaluate the role of cf-DNA in the diagno-
sis and differential diagnosis of sepsis.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics of septic patients
Variable Sepsis (n = 24)
Age (y) 58.3 ± 12.7
Sex (M/F) 15/9
Primary diagnosis
Major surgery 10
Intestinal obstruction 5
Intestinal perforation 3
Mesentric vein thrombosis 2
Abdominal or pelvic abscess 1
Multiple trauma 3
Site of infection
Abdomen 10
Thorax 6
Blood 4
Others 4
Pathogen types
Gram-negative infection 13
Gram-positive infection 8
Fungi 3
APACHE II 18.2 ± 6.6
Survivors 15
Nonsurvivors 9
Septic shock 9
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2.1. Participants and sample preparation
Sixty-seven consecutive patients who presented to the Medical ICU
of SongJiang Central Hospital (Shanghai, China) over a 1-year period
participated in the study. Samples were taken within 6 hours after the
onset of clinical syndromes without treatment. For the SIRS group, pa-
tients had to fulﬁll at least 2 criteria of SIRS but have no evidence of
organ dysfunction or sepsis. For the sepsis group, patients had to fulﬁll
both the criteria for SIRS andhavemicrobiological evidence of local infec-
tion. Bacteria, fungi, or parasites were cultured from the blood of all sep-
sis patients. Systemic inﬂammatory response syndrome patients had no
symptoms of local infection, and nomicroorganismswere cultured from
their blood. The causes of sepsis included major surgery, multiple
traumas, intestinal perforation, and intestinal obstruction. Age-matched
healthy volunteers (n = 73) were recruited as healthy controls.
For serum separation, blood samples were collected into clot activa-
tion additive-containing tubules, centrifuged at 1600g for 10 minutes,
followed by 16000g for 1minute. The supernatant (serum)was collect-
ed into a clear tube and stored at−80°C until use. The institution ethics0
500000
1000000
1500000
2000000
2500000
3000000
3500000
4000000
4500000
0 20 40 60 80 100 120
Alu (ng/ml)
R
LU
 (R
ela
tiv
e L
um
ine
sc
en
ce
 U
nit
)A B
Fig. 1. Cell-free circulating DNA concentration in control subjects, SIRS patients, and sepsis pati
with a correlation coefﬁcient of 0.991. B, Cell-free circulating DNA concentration in control sub
(n= 48), 692.02 ± 703.06 in SIRS patients (n = 43), and 1426.54 ± 863.79 ng/mL in sepsis p
serum cf-DNA between any two of the groups (P= .000).committee approved this study, and informed written consent was ob-
tained from each patient.2.2. Cell-free circulating DNA quantiﬁcation
Serum (20 μL) was added to a working probe set (80 μL) working solu-
tion that contained lysis buffer, proteinase K, and target gene probes
(Panomics, Santa Clara, CA). This mixture was transferred to a 96-well
plate thatwas incubated overnight (12-18 hours) at 55°C. After incubation,
plates were washed 3 times with 300 μL of washing buffer (Panomics).
Next, 100 μL of preampliﬁedworking solution, 100 μL of ampliﬁedworking
solution, and 100 μL of label probe working solution were sequentially
added to each well (Panomics). After each addition, the plate was hybrid-
ized for 1hour at 55°C, followedby another 3washes. Finally, 100 μL of sub-
stratewas added to eachwell, followed by incubation at room temperature
for 5 minutes. Luminescent signals were detected by Perkin Elmer Victor 3
(Perkin Elmer, Newark, NJ). The cf-DNA concentration was calculated ac-
cording to the standard curve simultaneously performed in the same plate.2.3. Procalcitonin and IL-6 quantiﬁcation
Procalcitonin and IL-6 concentrationswere evaluated by electrochem-
ical luminescence on a Roche COBAS-e601. This is an automated hetero-
geneous sandwich immunoassay, with a total assay time of 18 minutes.
A PCT concentration greater than 46 pg/mL is considered positive, where-
as an IL-6 concentration higher than 7 pg/mL is considered positive.2.4. Statistical analyses
Quantitative data are described as the mean ± SD. Statistical analyses
were performed using SPSS 13.0 for Microsoft Windows (SPSS, Chicago,
IL), except that MedCalcR4.20.011 (Frank Schoonjans, Mariakerke,
Belgium) was used to compare the receiver operating characteristic
(ROC) curve. For nonparametric data, Mann-Whitney U tests were per-
formed for comparisons between 2 groups. Correlations between 2 quanti-
tative variables are expressed by Spearman correlation coefﬁcient. Receiver
operating characteristic curves were applied to assess the predictive value
of cf-DNA, and the area under curve (AUC) was calculated and compared.
Conﬁdence intervals for areas under ROC curves were calculated using
nonparametric assumptions. A 2-sided P b .05 was considered sta-
tistically signiﬁcant.Controls SIRS Sepsis
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ents. A, Cell-free circulating DNA concentration standard curve. A typical calibration curve
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atients (n = 24). Nonparametric Mann-Whitney U tests showed signiﬁcant differences in
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Fig. 2. Correlations between serum levels of cf-DNA and PCT or IL-6 in 24 specimens from septic patients. A, PCT vs cf-DNA (r= 0.717; P b .001). B, IL-6 vs cf-DNA (r= 0.481; P= .017).
Fig. 3. Receiver operating characteristic curves of cf-DNA. A, Normal vs SIRS (AUC, 0.763; P= .000). B, Normal vs sepsis (AUC, 0.955; P= .000). C, SIRS vs sepsis (AUC, 0.856; P= .000).
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3.1. General characteristics of the patients
The characteristics of the patients are shown in Table 1. The leading
causes of sepsis were major surgery, intestinal obstruction, intestinal
perforation, and multiple traumas. Abdomen, thorax, and blood were
the primary sites of infection for both gram-negative and gram-
positive infections. All sepsis patients were admitted to the ICU.
The 43 SIRS patients had amean age of 55.4±10.6 years. Therewere
26 males and 17 females, and organ dysfunction and sepsis were not
found. We recruited 73 healthy volunteers (45 males and 28 females)
with a mean age of 52.6 ± 12.9 years.
3.2. Detection with bDNA-based Alu assays
The sensitivity, speciﬁcity, accuracy, and reproducibility of Alu-
based assays have been described in previous studies [21]. In thisTable 2
Diagnostic performance of cf-DNA in SIRS and sepsis
Groups Area SE P 95% CI
Lower bound
Normal vs SIRS 0.763 0.052 .000 0.661
Normal vs sepsis 0.955 0.036 .000 0.884
SIRS vs sepsis 0.856 0.048 .000 0.749study, serial 2-fold dilutions of standard human genomic DNA were
used. Standard curves showed the linear correlation (R2 = 0.991) was
out of range (0-100ng/mL) of the cf-DNA concentration, and the formu-
la for the regression line was y = 2 × 10−5x (Fig. 1A).
3.3. Serum cf-DNA levels
The bDNA-based Alu assays revealed that serum cf-DNA levels were
signiﬁcantly increased in septic patients (1426.54 ± 863.79 ng/mL) and
SIRS patients (692.02 ± 703.06 ng/mL) compared to healthy controls
(69.66 ± 24.66 ng/mL; P b .05). Compared to SIRS patients, the serum
cf-DNA of septic patients was also signiﬁcantly elevated (P b .05) (Fig. 1B).
3.4. Correlation of cf-DNA with PCT and IL-6
Serum cf-DNA levels were elevated in all sepsis patients. The corre-
lation of cf-DNA concentration with PCT or IL-6 was PCT vs cf-DNA (r=
0.717; P b .001) and IL-6 vs cf-DNA (r= 0.481; P= .017) (Fig. 2).Cutoff (ng/mL) Sensitivity (%) Speciﬁcity (%)
Upper bound
0.865 228.5 72.1 72.6
1.025 385 91.7 88.6
0.929 493 94.1 70.6
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Fig. 4. Receiver operating characteristic curves of PCT, IL-6, and cf-DNA in differential diag-
nosis between SIRS and sepsis.
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Receiver operating characteristic curves were generated to evaluate
the sensitivity and speciﬁcity of cf-DNA in the diagnosis of SIRS and sep-
sis. The AUC of cf-DNA was 0.763 (95% conﬁdence interval [CI], 0.611-
0.865) for SIRS (Fig. 3A) and 0.955 (95% CI, 0.884-1.025) for sepsis
(Fig. 3B). At a cutoff value of 228.5 ng/mL, cf-DNA gave a sensitivity of
72.1% and a speciﬁcity of 72.6% for SIRS. The optimal cutoff value of cf-
DNA was 385 ng/mL in the prediction of sepsis, which had a sensitivity
of 91.7% and a speciﬁcity of 88.6% (Table 2).
Furthermore, ROC curves were also used to distinguish SIRS
from sepsis. The AUC of cf-DNA was 0.856 (95% CI, 0.749-0.929)
for distinguishing SIRS from sepsis (Fig. 3C). With a cutoff value
of 493 ng/mL, cf-DNA yielded a sensitivity of 94.1% and a speciﬁcity
of 70.6% (Table 2).
3.6. Comparisons with other clinical parameters in differential diagnosis
between SIRS and Sepsis
To compare cf-DNA with other clinical indicators used in the differ-
ential diagnosis of sepsis and SIRS, the serum levels of PCT and IL-6were
measured in all blood samples. As shown in Fig. 4 and Table 3, cf-DNA is
the best index with a sensitivity of 94.12% and a speciﬁcity of 70.59% at
the cutoff value of 493 ng/mL for diagnosing sepsis. The AUC of PCTwas
0.807 (95% CI, 0.693-0.893) for distinguishing SIRS from sepsis. With a
cutoff value of 0.125 ng/mL, PCT yielded a sensitivity of 92.12% and a
speciﬁcity of 55.88%. Interleukin 6 is an acute inﬂammatory molecule
with a sensitivity of 35.29% and a speciﬁcity of 88.24% at the cutoff
value of 242.6 pg/mL for the diagnosis of sepsis. The AUC of IL-6 was
0.606 (95% CI, 0.480-0.723) for distinguishing SIRS from sepsis. The pre-
diction sensitivity, positive predictive value, and negative predictive
value for cf-DNA, IL-6, and PCT are listed in Table 3. Therefore, our
data suggest that serum cf-DNA level is comparable to, or better than,Table 3
Diagnostic performance of PCT, IL-6 and cf-DNA in differential diagnosis between SIRS and sep
Discrimination sepsis from SIRS cf-DNA (ng/mL)
Optical cutoff points 493
AUC ± SEM (95% CI) 0.856 ± 0.048 (0.749-0.929)
Sensitivity, % (95% CI) 94.12% (80.3-99.3)
Speciﬁcity, % (95% CI) 70.59% (52.5-84.9)
Positive likelihood ratio (95% CI) 3.2 (1.9-5.4)
Negative likelihood ratio (95% CI) 0.083 (0.02-0.3)
Positive prediction value, % (95% CI) 76.2 (60.5-87.9)
Negative prediction value, % (95% CI) 92.3 (74.9-99.1)the 2 clinically used indicators. Cell-free circulating DNA could be a
new marker in discrimination of sepsis and SIRS.
3.7. Serum cf-DNA and disease severity
The Acute Physiology and Chronic Health Evaluation (APACHE) II
score represents the severity of sepsis. We evaluated the correlation of
cf-DNA with the severity of sepsis (APACHE II score). Our results dem-
onstrate that serum cf-DNA levels signiﬁcantly correlated with the
APACHE II score (r= 0.496; P= .014) (Fig. 5A). In addition, serum cf-
DNA levels were signiﬁcantly higher on admission in ICU patients who
did not survive compared to patients who survived (2183.33 ±
615.26 vs 972.46 ± 648.36 ng/mL; P b .05) (Fig. 5B).
4. Discussion
Because sepsis remains an important cause of mortality in the ICU,
early and rapid diagnosis and treatment are essential. The classic
markers for sepsis diagnosis include fever and leukocyte count. Al-
though these are easy to measure, they are insensitive and nonspeciﬁc
[22]. Currently, there is controversy regarding the role of new markers,
such as PCT and CRP, in the diagnosis of sepsis [23,24]. Microbiological
culture is the bestway to diagnose sepsis; however, it is time consuming
and typically takes 24 to 48 hours. Thus, it is imperative to ﬁnd better
markers for the diagnosis of sepsis and the differential diagnosis of sep-
sis and SIRS.
Cell-free circulating DNA can be detected by various methods, but
nearly all methods require sample preparation. Alu sequences are
small interspersed elements that account for greater than 10% of the
human genome. Whole blood is rich in Alu sequences. Assaying Alu se-
quences represents a sensitive new method for the measurement of
blood cf-DNA. In the present study, novel bDNA-based Alu assays
were performed to directly quantify serum cf-DNA levels. This method
avoids the DNA extraction and puriﬁcation and requires only 20 μL of
serum for 1 test. In addition, it has high sensitivity and reproducibility
with a dynamic range of 0 to 400 ng/mL human genomic DNA [21].
The results of this study show that serum cf-DNA could comple-
ment CRP and PCT measurements for the diagnosis of sepsis. First,
serum cf-DNA concentration was signiﬁcantly increased in septic pa-
tients compared to healthy controls (1426.54 ± 863.79 vs 69.66 ±
24.66 ng/mL; P b .05). Receiver operating characteristic curve analy-
ses revealed that serum cf-DNA at a cutoff value of 385 ng/mL yielded
a sensitivity of 91.7% and a speciﬁcity of 88.6% for the diagnosis of
sepsis. Second, although we observed increased serum cf-DNA in
both septic and SIRS patients, the extent of their elevation was mark-
edly different. The average cf-DNA was 1426.54 ± 863.79 ng/mL in
sepsis patients and 692.02 ± 703.06 ng/mL in SIRS patients. At a cut-
off value of 522 ng/mL, serum cf-DNA yielded a sensitivity of 91.7%
and a speciﬁcity of 60.5% for a differential diagnosis between sepsis
and SIRS. In addition, serum cf-DNA levels positively correlated
with previous indicators such as CRP and PCT and yielded compara-
ble or better sensitivity and speciﬁcity compared to these indicators.
Serum cf-DNA also positively correlated with the APACHE II score,
the most commonly used index to evaluate sepsis severity (r =sis
IL-6 (pg/mL) PCT (ng/mL)
242.6 0.125
0.606 ± 0.072 (0.480-0.723) 0.807 ± 0.053 (0.693-0.893)
35.29 (19.7-53.5) 92.12 (80.3-99.3)
88.24 (72.5-96.7) 55.88 (37.9-72.8)
3.00 (1.1-8.4) 2.13 (1.4-3.1)
0.73 (0.6-1.0) 0.11 (0.03-0.4)
75.0 (47.6-92.7) 68.1 (52.9-80.9)
57.7 (43.1-71.3) 90.5 (69.6-98.9)
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Fig. 5. Serum cf-DNA and disease severity. A, Correlation between cf-DNA and APACHE II scores in septic patients. Cell-free circulating DNA levels signiﬁcantly correlated with APACHE II
scores in septic patients (r= 0.496; P= .014). B, Cell-free circulating DNA concentrations in septic patients who survived or died in the ICU. Serum cf-DNA was 972.46 ± 648.36 in sur-
viving patients and 2183.33 ± 615.26 ng/mL in nonsurviving patients. Mann-Whitney U tests indicated signiﬁcant differences between the 2 groups (P= .000).
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higher cf-DNA concentrations compared to surviving patients,
which is consistent with previous reports [25,26]. Because the sam-
ple size was relatively small in this study, the number of deaths
was not sufﬁcient to evaluate the independent effect of serum cf-
DNA level on mortality. In addition, this study was not designed to
evaluate the predictive power of serum cf-DNA for sepsis. However,
the serum cf-DNA concentrations in this study were in agreement
with previous reports, suggesting that the novel bDNA-based Alu
assay is a potentially feasible and useful method to detect cf-DNA
levels in clinical settings. Because cf-DNA levels are elevated in septic
patients compared to healthy controls, it could be useful for the diag-
nosis and differential diagnosis of sepsis.
Notably, although the serum cf-DNA levels signiﬁcantly differed be-
tween SIRS and septic patients, there was still overlap in the serum cf-
DNA levels between them. We speculate that high cf-DNA levels in
some SIRS patients might contribute to early infection by certain patho-
gens at an undetectable level, representing the transition from SIRS to
sepsis. Similarly, low cf-DNA levels in some septic patients might be re-
lated to the transition from sepsis to recovery. Therefore, serum cf-DNA
might be valuable in predicting therapeutic outcomes. Future studies
with larger sample sizes will be conducted with side-by-side assess-
ments with other indicators to validate this hypothesis.
The origin of circulating DNA is still unclear. It appears that circulat-
ing DNA in cancer patients is derived from cancer cells. It has been pro-
posed that circulating DNA may be a result of cellular necrosis and/or
apoptosis [27,28]. However, recent studies reveal that the cf-DNA levels
do not always correspond to the amount of circulating cancer cells, sug-
gesting that circulating DNA may be actively secreted by cancer cells as
well as other cells under stress [29]. Hehlgans and Pfeffer [30] found
that, in addition to necrosis and apoptosis, other cellular stresses may
be potential mechanisms of cf-DNA secretion. Clearly, more studies in
this ﬁeld are necessary.
The exact mechanism of serumDNA clearance also remains unclear.
It has been suggested that the liver and kidney have important roles in
the clearance of circulating DNA. Inmice, nucleotides are predominately
metabolized in the liver [31]. Botezatu et al [32] found that approxi-
mately 0.5% to 2% of circulating DNA crossed the kidney barrier and
was excreted in the urine. Therefore, high circulating DNA levels may
contribute to poor renal or liver function or to increased cellular dam-
age/secretion, which thus questions circulating DNA as a biomarker.
Although many studies have demonstrated that the serum cf-DNA
level is a promising biomarker for several diseases, our current data are
preliminary. Thus, further studies are required to determine the speciﬁc
role of circulating DNA in sepsis, including the correlation between cf-DNA and organ injury and the mechanisms of cf-DNA release. These data
should provide important information regarding the diagnosis of sepsis.
In conclusion, our ﬁndings demonstrate that the bDNA-based Alu
assay is a novel and feasible method to quantify human cf-DNA.
Serum cf-DNA provides comparable or better sensitivity and speciﬁcity
compared with previous indicators and might complement CRP, PCT,
and IL-6 in a multiple marker format. However, there were only 24 sep-
tic patients in this study. Larger studies are needed in the future to eval-
uate the diagnostic value of serum cf-DNA in sepsis and SIRS.
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